Loading...
Market
How many private prescriptions for Lecanemab in UK by end of 2024?
2
Resolution / Starting Odds
Less than 500 • 25%
500 to 1000 • 25%
1001 to 2000 • 25%
More than 2000 • 25%
Data from the UK's Medicines and Healthcare products Regulatory Agency (MHRA), major news outlets
Story
UK Approves Alzheimer's Drug Lecanemab for Early-Stage, Not Available on NHS, Private Prescription Possible
Aug 22, 2024, 07:25 AM
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved the Alzheimer's drug Lecanemab, marking a significant development in the treatment of early-stage Alzheimer's disease. Lecanemab is the first drug shown to slow the progression of Alzheimer's, offering hope for patients. However, despite its approval, the drug will not be available through the National Health Service (NHS) due to its high cost, limiting access for many patients. The drug, developed by Eisai and Biogen and marketed as Leqembi, can be prescribed privately and represents a major advancement in Alzheimer's treatment, though experts caution it is not a 'wonder drug' but an important step forward.
View original story
Similar markets
Less than 10,000 • 25%
10,000 to 20,000 • 25%
20,000 to 30,000 • 25%
More than 30,000 • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
0-10,000 • 25%
10,001-20,000 • 25%
20,001-30,000 • 25%
Over 30,000 • 25%
0-1 • 25%
2-5 • 25%
6-10 • 25%
More than 10 • 25%
Less than 1,000 • 25%
1,000 to 5,000 • 25%
5,001 to 10,000 • 25%
More than 10,000 • 25%
Approved for preventive use • 25%
Approved with restrictions • 25%
Rejected • 25%
No decision • 25%
Less than 500 • 25%
500-1000 • 25%
1001-2000 • 25%
More than 2000 • 25%
Less than 5,000 • 25%
5,000 - 10,000 • 25%
10,000 - 15,000 • 25%
More than 15,000 • 25%
Less than 1 million • 25%
1 million to 2 million • 25%
2 million to 3 million • 25%
More than 3 million • 25%